نتایج جستجو برای: myeloablative

تعداد نتایج: 1963  

Journal: :Journal of Korean Medical Science 2003
Gyeong-Won Lee Je-Hwan Lee Soon-Bae Kim Eun-Sil Yu Jae-Lyun Lee Min-Hee Ryu Eunkyoung Kim Seong-Jun Choi Woo-Kun Kim Jung-Shin Lee Kyoo-Hyung Lee

Allogeneic stem cell transplantation (allo-SCT) using related or unrelated donor could eradicate paroxysmal nocturnal hemoglobinuria (PNH) clones and may cure the disease. Chronic graft-versus host disease (GVHD) is a major complication of patients who have undergone allo-SCT. Nephrotic syndrome has been described as one of the rare manifestations of chronic GVHD following the usual myeloablati...

2004
Suk Joong Oh Kyoo Hyung Lee Je Hwan Lee Seong Jun Choi Woo Kun Kim Jung Shin Lee Mi Na Kim

Non-myeloablative allogeneic peripheral stem cell transplantation (NST) is a novel therapeutic strategy for patients with hematologic malignancies. Whether non-myeloablative transplants are associated with increased risk of cytomegalovirus (CMV) infections is unknown. To clarify this issue, we compared the outcome of CMV infection following 24 allogeneic non-myeloablative peripheral blood stem ...

2013
Kia J. Langford-Smith Zara Sandiford Alex Langford-Smith Fiona L. Wilkinson Simon A. Jones J. Ed Wraith Robert F. Wynn Brian W. Bigger

Non-myeloablative allogeneic haematopoietic stem cell transplantation (HSCT) is rarely achievable clinically, except where donor cells have selective advantages. Murine non-myeloablative conditioning regimens have limited clinical success, partly through use of clinically unachievable cell doses or strain combinations permitting allograft acceptance using immunosuppression alone. We found that ...

2002
CP Anderson CP Reynolds

Patients with high-risk neuroblastoma (NB) initially respond to aggressive, alkylator-based therapy only to die from recurrent disease that is refractory to chemotherapy, including alkylating agents. We examined the ability of buthionine sulfoximine (BSO)-mediated glutathione (GSH) depletion to modulate melphalan (LPAM) resistance in five NB cell lines established after progressive disease foll...

Journal: :Blood 1997
A Freedman D Neuberg P Mauch J Gribben R Soiffer K Anderson M Robertson D C Fisher R Schlossman M Kroon C Rhuda C Kuhlman J Ritz L Nadler

Hematopoietic growth factors allow dose escalation of chemotherapy. This approach may potentially reduce the quality and quantity of hematopoietic stem cells. The capacity of stem cells recovered after dose intensification to support myeloablative therapy is unknown. In patients with previously untreated advanced follicular lymphoma, trilineage hematopoietic engraftment was compared in two sequ...

Journal: :Blood 2005
Edwin P Alyea Haesook T Kim Vincent Ho Corey Cutler John Gribben Daniel J DeAngelo Stephanie J Lee Sarah Windawi Jerome Ritz Richard M Stone Joseph H Antin Robert J Soiffer

Nonmyeloablative stem cell transplantation (NST) is increasingly used in older patients. The impact of the shift from myeloablative transplantation to NST on relapse, transplant complications, and outcome has yet to be fully examined. We performed a retrospective analysis of 152 patients older than 50 years undergoing NST or myeloablative transplantation. Seventy-one patients received nonmyeloa...

Journal: :Blood 2008
Charles G Mullighan Susan L Heatley Silke Danner Melinda M Dean Kathleen Doherty Uwe Hahn Kenneth F Bradstock Robyn Minchinton Anthony P Schwarer Jeff Szer Peter G Bardy

Mannose-binding lectin (MBL) is a mediator of innate immunity that influences the risk of infection in a range of clinical settings. We previously reported associations between MBL2 genotype and infection in a retrospective study of myeloablative allogeneic hematopoietic stem cell transplantation (allo-HCT). However, other studies have been inconclusive, and the role of MBL in reduced-intensity...

Journal: :Acta haematologica 2013
Zhixin Sheng Huanwen Ma Wenzheng Pang Shanona Niu Jingbo Xu

To assess the effect of prophylactic treatment with antithymocyte globulin (ATG) on graft-versus-host disease (GvHD) in myeloablative transplant patients, we performed a meta-analysis of randomized and cohort studies. Medline, Embase, the Cochrane Controlled Trial Register and the Science Citation Index were searched for studies on ATG treatment in patients with hematologic disorders undergoing...

2014
Pamela Paplham Theresa Hahn Karen Dubel Patricia Lipka Philip L. McCarthy

Non-myeloablative allogeneic transplant (NMAT) has a curative potential for patients who are not myeloablative allogeneic transplant (MAT) candidates. We report a phase II trial of a NMAT regimen with cyclophosphamide and fludarabine in 40 patients; 21 of whom had a prior MAT. Day +100 and 1-year transplant-related mortality (TRM) post-NMAT were 13% and 34%, respectively. Day +100 and 1-year Ov...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید